Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

eutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to FDA clearance. Based on preliminary discussions with the FDA, CytRx is now considering a second efficacy clinical trial for ALS, possibly in parallel with the upcoming Phase IIb trial, to provide additional efficacy data to support a possible approval decision by the FDA.

The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS, which has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.

About RXi Pharmaceuticals Corporation

Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014 The American Association for ... Design and Manufacturing has joined the AAHomecare Corporate Partner ... Harvey Diamond have been actively involved in AAHomecare ... it has quickly grown into a major global manufacturer ... Drive allows AAHomecare to increase efforts on behalf of ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... 2014 Larry J. Merlo , President and ... speak before the National Press Club in Washington, ... move to stop selling tobacco products and its leadership in ... "Dramatic changes in our health care system pose ... Merlo has said. "CVS Health has a truly unique combination ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... Pharmaceutical Services is pleased to announce the exciting addition ... as the new Manager of Minerals.  Dr. Al-Ammar brings ...  Al-Ammar has over fourteen years of experience with ICP-MS ... the United States and Europe.  Additionally, Dr. Al-Ammar has ...
... MedNet Solutions, a global life sciences technology solutions company ... announce that MedNet will be showcasing its full lineup ... Association (DIA) Annual Meeting in Chicago, IL on June ... release of iMedNet EDC earlier this year, MedNet now ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2MedNet Solutions to Showcase Its Complete Suite of eClinical Solutions at the 47th DIA Annual Meeting 2
(Date:9/19/2014)... women who live in leafy, green neighborhoods are less likely ... study suggests. Researchers analyzed data from more than 64,000 ... lived in a neighborhood with plenty of trees, grass and ... preterm birth (before 30 weeks) and a 13 percent lower ... Babies born to mothers who lived in greener neighborhoods were ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. 18, ... and family conflicts before surgery may face a higher ... suggests. Investigators found that patients with a so-called ... greater risk for complications compared to those with a ... known that patient quality of life is a complex ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 In partnership with ... been an active part of the project’s social media efforts. ... which aims to re-define the perception of beauty as it ... began as an idea by Shelly Baer and Vanessa Silberman, ... women as sexy and beautiful. Ginny Dixon, Wendy Crawford, Susan ...
(Date:9/19/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
Breaking Medicine News(10 mins):Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2
... cycles, known as circadian rhythms, are important for proper ... health. Disruptions of circadian rhythms and sleep-wake cycles have ... study by Douglas Institute researchers unravels a possible basis ... of clock genes in multiple areas of the human ...
... April, 2011: In the context of rising levels of cardiovascular ... of Cardiology (ESC) announces that for the first time- the ... Asia Pacific Congress of Cardiology (APCC). The 18th edition ... Malaysia, from 5 to 8 May 2011. The ESC deputation ...
... producing large quantities of a much-needed new imaging agent for ... other diseases, and the first evidence that the material is ... oxide nanoparticle, which is inexpensive, and stays in the body ... in the Journal of the American Chemical Society . ...
... a compound derived from tobacco, reduced plaques associated with dementia ... disease, a study led by researchers at Bay Pines VA ... The findings are reported online in the Journal ... "We found a compound that protects neurons, prevents the progression ...
... research shows that high maternal viral load and co-infection ... factors associated with vertical transmission of the hepatitis C ... (CC) is associated independently with the spontaneous clearance of ... in the mother or children did not increase risk ...
... -- Global Bridges, a healthcare alliance for tobacco dependence ... the InterAmerican Heart Foundation (IAHF) in Dallas, Texas, announced ... for health care providers in Latin America on how ... developed in collaboration with several regional and global expert ...
Cached Medicine News:Health News:Researchers observe disruptions of daily rhythms in Alzheimer's patients' brains 2Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:Tobacco-derived compound prevents memory loss in Alzheimer's disease mice 2Health News:Severity of hepatitis C and HIV co-infection in mothers contribute to HCV transmission to child 2Health News:Health care alliance for tobacco dependence treatment launches training in Mexico 2Health News:Health care alliance for tobacco dependence treatment launches training in Mexico 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: